Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, L Zhang et al.|The Lancet Oncology|2011Cited by 4.1k
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung CancerRamaswamy Govindan, Martin Reck, Baohui Han et al.|Journal of Clinical Oncology|2017Cited by 380
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung CancerJames Chih‐Hsin Yang, Gongyan Chen, Dae Ho Lee et al.|Journal of Clinical Oncology|2024Cited by 137